

23 February 2010

**Plethora Solutions Holdings plc  
(‘Plethora’)**

**Notice of Results**

Plethora (AIM: PLE), the UK-based specialty pharmaceutical company, will announce its preliminary results for the period ended 31<sup>st</sup> December 2009 on Tuesday 9<sup>th</sup> March 2010.

**Enquiries:**

**Plethora Solutions**  
Steven Powell

**Tel : +44(0) 20 3077 5400**

**FinnCap**  
Geoff Nash

**Tel: +44(0) 20 7600 1658**

**Hansard Group**  
Adam Reynolds/John Bick

**Tel: +44(0) 20 7245 1100**

**About Plethora:**

Plethora is focused on the development and marketing of products for the treatment of urological disorders. The Company has products in clinical development for the treatment of overactive bladder (PSD506), stress urinary incontinence (PSD503), interstitial cystitis (PSD597), gynaecological pain (PSD508), erectile dysfunction (PSD510) and premature ejaculation (PSD502). Plethora's subsidiary, The Urology Company Limited, was established in 2009 to market and distribute a range of therapeutic products for the treatment of urology, andrology and obstetric conditions. The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE.L).

Further information is available at [www.plethorasolutions.co.uk](http://www.plethorasolutions.co.uk).